Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) CFO Stephen Feider sold 6,676 shares of the stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $84,184.36. Following the sale, the chief financial officer directly owned 166,053 shares in the company, valued at approximately $2,093,928.33. The trade was a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Beta Bionics Stock Down 2.7%
BBNX opened at $12.45 on Thursday. The business’s fifty day simple moving average is $10.83 and its 200 day simple moving average is $17.31. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71. The firm has a market cap of $554.59 million, a P/E ratio of -8.24 and a beta of 3.40.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last issued its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The firm had revenue of $27.63 million for the quarter. As a group, equities analysts expect that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
BBNX has been the topic of several research analyst reports. Bank of America decreased their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Stifel Nicolaus decreased their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Robert W. Baird reduced their price objective on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. UBS Group raised Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. Finally, Weiss Ratings lowered Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Beta Bionics has a consensus rating of “Moderate Buy” and a consensus price target of $19.70.
Get Our Latest Stock Report on BBNX
More Beta Bionics News
Here are the key news stories impacting Beta Bionics this week:
- Positive Sentiment: Beta Bionics said it is now publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support investor confidence in the company’s commercial progress and transparency. Article Title
- Neutral Sentiment: Several top executives disclosed stock sales on June 2, including CFO Stephen Feider and insiders Steven Jon Russell, Mark Hopman, and Mike Mensinger. Each sale was relatively small and was stated to be for tax withholding related to vesting equity awards, which makes the transactions less concerning than open-market selling, but the volume may still weigh on sentiment.
- Negative Sentiment: Multiple law firms, including Robbins LLP and Johnson Fistel, announced investigations into Beta Bionics and its officers/directors over possible securities-law violations and investor losses. These headlines suggest litigation risk and can spark concerns about disclosure practices and governance. Article Title
- Negative Sentiment: A shareholder alert said Robbins LLP is investigating whether Beta Bionics executives and directors violated securities laws and breached fiduciary duties, adding to the legal overhang. Article Title
- Negative Sentiment: Johnson Fistel also said it is investigating whether investors suffered losses after Beta Bionics reported slower new patient start growth, highlighting concerns that growth momentum may be decelerating. Article Title
About Beta Bionics
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Featured Articles
- Five stocks we like better than Beta Bionics
- Dell’s AI Toll Bridge Is Paved with Record Margins
- As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingAI
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
